Sunesis to Acquire Anticancer Compound From Bristol-Myers Squibb

Sunesis Pharmaceuticals announced that it has obtained worldwide development and commercialization rights to BMS-387032 (now SNS-032), a targeted small molecule anticancer compound from Bristol-Myers Squibb Company. SNS-032 is a novel cyclin dependent kinase (CDK) inhibitor that induces cell-cycle arrest and apoptosis. This clinical-stage compound is the third cell-cycle inhibitor in Sunesis' proprietary oncology portfolio. Under the terms of the agreement, Bristol-Myers Squibb will receive an up-front equity stake of $8 million in Sunesis.

PharmaLive (http://www.pharmalive.com/News/index.cfm?articleid=234073&categoryid=21)